At a glance
ClinicalIndex Comparison Record- ✓African American men and women
- ✓Age 18-50 years
- ✓BMI 25-40 kg/m²
- ✕Diabetes type 1 or type 2 (FPG >126 mg/dL, 2-hour glucose >200 mg/dL, or on anti-diabetic medication)
- ✕Pulmonary hypertension
- ✕Prior use of PDE5 inhibitor for erectile dysfunction
- ✕Cardiovascular disease (MI, angina, significant arrhythmia, CHF, DVT, PE, heart block, valve disease, hypertrophic cardiomyopathy)
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Role of CD36 in Nutrient Delivery and Its Dysfunction in African Americans
In Brief
A Phase 2 clinical trial evaluating Sildenafil Citrate in G allele carrier and Sildenafil Citrate in non G allele carrier for Insulin Resistance and Endothelial Dysfunction. Completed, enrolled 26 participants across 1 site.
Detailed Summary
This proposal will test the hypothesis that chronic treatment with sildenafil with and without the use of nitric oxide substrate, L-arginine, protects against fatty acid induced impairment of endothelial function, improves insulin-stimulated microvascular recruitment, insulin sensitivity and glucose uptake in CD36 rs3211938 G-allele carriers.
Study Details
Timeline
Interventions
chronic use of phosphodiesterase 5 inhibitor in G allele carrier
chronic use of phosphodiesterase 5 inhibitor in Non G allele carrier